uniQure (QURE) Expected to Announce Earnings on Wednesday

uniQure (NASDAQ:QURE) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect uniQure to post earnings of ($0.60) per share and revenue of $18.45 million for the quarter.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $13.25 on Wednesday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The firm has a market cap of $645.81 million, a PE ratio of -2.67 and a beta of 0.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The business has a fifty day moving average of $15.68 and a 200-day moving average of $9.50.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on QURE shares. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Cantor Fitzgerald lifted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group lifted their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.